Enzalutamide plus Talazoparib for the Treatment of Hormone Sensitive Prostate Cancer

Phase 1

• Conditions: Metastatic hormone–naïve prostate cancer (mHNPC); MedDRA version: 21.1Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps); MedDRA version: 21.0Level: PTClassification code 10036920Term: Prostate cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps); Therapeutic area: Diseases [C] - Cancer [C04]

• Registration Number: EUCTR2019-003096-20-ES
• Lead Sponsor: Medica Scientia Innovation Research S.L. (MEDSIR)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-05-31
• Last Update Posted: 30 November 2020

Recruitment & Eligibility

• Status: Authorised-recruitment may be ongoing or finished
• Sex: Male
• Target Recruitment: 54

Inclusion Criteria

1. Adult patients (>18 y.o.) who signed informed consent form (ICF) prior to participation in any study-related activities.
2. Willing and able to comply with scheduled visits, treatment plan,
laboratory tests, and other study procedures.
3. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0
or 1.
4. High-volume metastatic disease documented on bone scan or computed tomography (CT)/magnetic resonance imaging (MRI) scan, defined as the presence of either visceral disease and/or at least four bone metastases on bone scan, with at least one of them beyond spine/pelvis.
5. Life expectancy of = 12 months.6. Histologically confirmed adenocarcinoma of the prostate without predominance of small-cell or neuroendocrine features according to American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines based on local testing on the most recent analyzed biopsy.
Note: Central confirmation of adenocarcinoma is not required for study
entry. However, tissue blocks, or slides, must be submitted to confirm the diagnoses by a Sponsor-designated central laboratory retrospectively and/or exploratory biomarker analyses.
7. Willingness and ability to provide tumor paired biopsies during the study participation in order to perform exploratory studies. At the study entry, the most recent tumor biopsy since last progression from either metastatic or primary tissues will be provided. If not feasible, patient eligibility should be evaluated by a Sponsor’s qualified designee.
8. Adequate hematologic and organ function within 28 days before the first study treatment on Cycle 1 Day 1, defined by the following:
a. Hematological:
i. White blood cell (WBC) count > 3.0 x 109/L;
ii. Absolute neutrophil count (ANC) > 1.5 x 109/L;
iii. Platelet count > 100.0 x109/L;
iv. Hemoglobin (Hb) > 9.0 g/dL.
Note: Patients receiving growth factors or blood transfusions within 14 days before obtaining the hematology values at screening will be excluded.
b. Hepatic:
i. Total bilirubin = 1.5 times the upper limit of normal (× ULN) (= 3 x ULN in the case of Gilbert’s disease);
ii. Aspartate transaminase (AST) and alanine transaminase
(ALT) = 2.5 × ULN (in the case of liver metastases = 5 × ULN);
iii. Alkaline phosphatase (ALP) = 2.5 × ULN (= 5 × ULN in the case of liver and/or bone metastases).
c. Renal:
i. Serum creatinine < 1.5 × ULN or creatinine clearance = 30 mL/min based on Cockcroft-Gault glomerular filtration rate estimation.
d. Coagulation:
i. International normalized ratio (INR) and activated partial thromboplastin time (aPTT) = 1.5 x ULN unless on medication known to alter INR and/or aPTT.
e. Nutritional status:
i. Serum Albumin = 2.8 g/dL.
9. Bisphosphonates or denosumab dosage must have been stable for at
least 4 weeks before Day 1 for patients receiving these therapies.
10. Patients must agree to use a condom when is engaged in sexual activity with a pregnant woman during the treatment period and for at least 90 days after last dose of enzalutamide or at least 120 days after last dose of talazoparib (PF-06944076), whichever occurs later. Patients must also agree to use an additional highly effective form of contraception or two effective contraceptive methods, when is engaged in sexual intercourse with a woman of childbearing potential during the treatment period and for at least 90 days after last dose of enzalutamide or at least 120 days after last dose of talazoparib (PF-06944076), whichever occurs later.
11. Must agree to re

Exclusion Criteria

1. Prior treatment with enzalutamide, apalutamide, darolutamide or
abiraterone acetate.
2. History of malabsorption syndrome or other condition that would interfere with enteral absorption or results in the inability or unwillingness to swallow pills.
3. Known hypersensitivity to recombinant proteins, or any excipient contained in the drug formulation for talazoparib (PF-06944076) and enzalutamide.
4. Prior systemic therapy for metastatic prostate cancer (mPCa).
Note: Initiation of androgen deprivation therapy (ADT) within 4 weeks prior
to study entry would be allowed (with or without first-generation
antiandrogens), providing a tumor biopsy sample was taken prior to
initiation of ADT is made available for biomarker studies and upon
approval by the sponsor. If patient was started on first-generation
antiandrogens, these would be discontinued on prior to randomization.
Note: Patients relapsing after having received an ADT-based regimen in
neoadjuvant or adjuvant setting will be suitable for the study if metastatic progression occured while on non-castrate testosterone levels or at least 12 months after discontinuation of ADT.
5. Treatment with approved or investigational cancer therapy within 28 days (or 5 half-lives of the drug? whichever is longer) prior to initiation of study treatment.
6. Known or suspected brain metastases or active leptomeningeal disease.
7. Symptomatic or impending spinal cord compression or cauda equina
syndrome.
8. Subject has a history of seizure or any condition that may predispose to seizure (i.e. prior significant brain trauma, brain vascular malformations, ...), or subjects that have had unexplained loss of consciousness or transient ischemic attacks within 1 year prior to scheduled Day 1 of treatment.
9. Therapeutic radiation therapy within 14 days (seven days for limited-field palliative radiotherapy) prior to study enrolment, or patients who have not recovered from radiotherapy-related toxicities to grade = 1 according to National Cancer Insitute ´s Common Terminology Criteria for Adverse Events (NCI-CTCAE) version (v.)5.0.
10. Major surgery (defined as requiring general anesthesia) or significant traumatic injury within 14 days of start of study drugs, or patients who have not recovered from the side effects of any major surgery.
11. History of another malignancy within three years of study enrollment with the exception of carcinoma in situ, non-melanoma skin carcinoma, or American Joint Committee on Cancer stage 0 or stage 1 cancer that has a remote probability of recurrence in the opinion of the investigator and the Sponsor’s Medical Monitor is required, or any concurrent malignancy for which the patient is receiving therapy.
12. Active uncontrolled infection at the time of enrollment.
13. Congenital long QT syndrome or Electrocardiogram (ECG) at screening with QT interval corrected using Fridericia's formula (QTcF) > 500 milliseconds.
14. Patients with clinically significant cardiovascular disease including but not limited to any of the following:
a. Stroke, transient ischemic attack, unstable angina pectoris,
or documented myocardial infarction within 12 months prior to study entry.
b. Symptomatic pericarditis or clinically significant pericardial
effusion or myocarditis.
c. Documented congestive heart failure (New York Heart
Association functional classification III- IV).
d. Uncontrolled, persistent hypertension defined as systolic
blood pressure > 170 mmHg or diastolic blood pressure > 100
mmHg.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified